PJP - Invesco Dynamic Pharmaceuticals ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
60.87
+0.08 (+0.13%)
At close: 3:55PM EDT
Stock chart is not supported by your current browser
Previous Close60.79
Open60.67
Bid59.21 x 800
Ask62.50 x 800
Day's Range60.20 - 61.00
52 Week Range58.29 - 74.29
Volume22,552
Avg. Volume26,900
Net Assets416.59M
NAV60.39
PE Ratio (TTM)N/A
Yield1.12%
YTD Return-1.03%
Beta (3Y Monthly)1.10
Expense Ratio (net)0.57%
Inception Date2005-06-23
Trade prices are not sourced from all markets
  • ETF Trends9 days ago

    Legal Troubles Beset Pharmaceutical Sector ETFs

    Pharmaceutical ETFs may be in trouble with legal troubles looming over the industry. The drugmaker segment recently sold-off after an amended civil antitrust complaint brought by more than 40 state attorneys ...

  • Pharma ETFs Down Despite Solid Q1 Results
    Zacks14 days ago

    Pharma ETFs Down Despite Solid Q1 Results

    Despite such robust results, pharma ETFs have been trending downward in a month.

  • ETF Trendslast month

    4 ETFs to Consider with Big Pharma on the Senate’s Hot Seat

    Big pharmaceutical companies were on the hot seat at Capitol Hill today with CVS Health, Cigna, Prime Therapeutics, Humana, and UnitedHealthcare's OptumRx testifying before the Senate Finance Committee on the rising cost of prescription drugs. Among the topics discussed included rebates paid by drug makers contributing to the high costs and the drug industry's pursuit of profits--all to shift the blame from the pharmaceutical companies to the drug makers. U.S. President Donald Trump has already lambasted the pharmaceutical industry for the rising costs associated with prescription drugs.

  • 4 Sector ETFs That Crushed S&P 500 in Decade-Old Bull Run
    Zacks2 months ago

    4 Sector ETFs That Crushed S&P 500 in Decade-Old Bull Run

    These sector ETFs emerged winners in the 10-year old bull market.

  • Why These Pharma ETFs Rallied on Thursday
    Zacks3 months ago

    Why These Pharma ETFs Rallied on Thursday

    A few pharma ETFs hit a one-month high on Feb 28. Why?

  • ETF Trends3 months ago

    Pharmaceutical ETFs Break Out on Horizon Pharma’s Positive Drug Results

    Pharmaceutical sector-related ETFs stood out Thursday after Horizon Pharma (HZNP) revealed positive test results for its treatment of thyroid eye disease, or TED. Among the better performing non-leveraged ETFs of Thursday, the First Trust Nasdaq Pharmaceuticals ETF (FTXH) rose 1.8%, Invesco Dynamic Pharmaceuticals ETF (PJP) gained 1.5% and SPDR Pharmaceuticals ETF (XPH) increased 2.3%. Horizon Pharma shares surged 32.5% Thursday following the release of positive test results in its Phase 3 trial of its thyroid eye disease drug, teprotumumab, TheStreet reports.

  • Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
    Zacks3 months ago

    Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

    Sector ETF report for PPH

  • A Look at Pharma ETFs Post Q4 Results
    Zacks3 months ago

    A Look at Pharma ETFs Post Q4 Results

    The strong results but downbeat guidance led to decent returns in the pharma ETFs over the past month.

  • Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus
    Zacks5 months ago

    Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus

    The news has put the spotlight on a number of healthcare ETFs, especially biotech and pharma, which could be the best ways for investors to tap the opportunity arising from the BMY-CELG deal.

  • How Bausch Health’s Financials Look in November
    Market Realist6 months ago

    How Bausch Health’s Financials Look in November

    Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017, a ~4% YoY decline. Bausch Health generated revenues of $6.26 billion over the first nine months of this year compared to $6.56 billion in the same period the prior year, reflecting a ~5% YoY decline.

  • ETF Strategies for the Midterm Elections
    Zacks7 months ago

    ETF Strategies for the Midterm Elections

    Investors should focus on some strategies as to which sector should they take positions or which should be avoided if bipartisan government forms.

  • 7 months ago

    ETF Plays for a Divided Midterm Elections

    With a contentious midterms election season coming up, many anticipate a split government that could potentially impact the way ETF investors ride the markets ahead. Some expectations point to Democrats winning back the House of Representatives and the Republicans maintaining a narrow hold on the Senate - Republicans currently dominate both chambers. "If the consensus expectation of a divided government turns out to be correct, the most likely political consequences would be an increase in investigations and uncertainty surrounding fiscal deadlines," David Kostin, Goldman's chief U.S. equity strategist, said in a note.

  • A Financial Overview of Bausch Health in October
    Market Realist7 months ago

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.

  • Investopedia7 months ago

    Top 5 Pharmaceutical ETFs for 2018

    The healthcare sector will continue to see political attention in the remainder of 2018, with the 2017 U.S. tax reform bill influencing it in a number of ways. Its repeal of mandated healthcare is likely to change demand and effect provider participation.

  • How Did Pharmaceutical ETFs Perform in Q3 2018?
    Market Realist8 months ago

    How Did Pharmaceutical ETFs Perform in Q3 2018?

    In this article, we’ll discuss several major ETFs in the pharmaceuticals sector and their third-quarter returns. The chart below compares the market capitalization of these pharmaceutical ETFs on October 3.

  • What’s Eli Lilly’s Valuation as of September 27?
    Market Realist8 months ago

    What’s Eli Lilly’s Valuation as of September 27?

    Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue compared to $5.8 billion in the second quarter of 2017.

  • Allergan’s SpotLyte and Lumivive System
    Market Realist8 months ago

    Allergan’s SpotLyte and Lumivive System

    On September 12, Allergan (AGN) announced the launch of SpotLyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. On September 6, Allergan announced the launch of its dual-acting product, the SkinMedica Lumivive System. SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.

  • SUPN’s Product Portfolio and Financial Guidance
    Market Realist8 months ago

    SUPN’s Product Portfolio and Financial Guidance

    Supernus Pharmaceuticals’ (SUPN) Trokendi XR generated revenues of $76.4 million in the second quarter, compared to $56.0 million in the second quarter of 2017, reflecting ~36.4% YoY (year-over-year) growth.

  • ETF Trends9 months ago

    Pharmaceutical ETFs Could Maintain Their Momentum

    Pharmaceutical stocks and sector-related exchange traded funds have enjoyed a great summer and the rally may continue to have legs. Meanwhile, the broader iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) rose 10.6%. There were no clear catalysts to explain the rally as we did not witness any memorable earnings beats, new clinical trials or large-scale deals, the Wall Street Journal reports.

  • Is Projprzem SA’s (WSE:PJP) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.9 months ago

    Is Projprzem SA’s (WSE:PJP) Balance Sheet Strong Enough To Weather A Storm?

    Investors are always looking for growth in small-cap stocks like Projprzem SA (WSE:PJP), with a market cap of zł115.47m. However, an important fact which most ignore is: how financially healthyRead More...

  • Examining Pfizer’s Performance by Geography in Q2 2018
    Market Realist9 months ago

    Examining Pfizer’s Performance by Geography in Q2 2018

    Pfizer (PFE) reported a rise in revenue in international markets during the second quarter. The Innovative Health segment reported a rise of 3% in revenue to ~$4.58 billion, while the Essential Health segment reported a ~14% fall in revenue to $1.65 billion. The rise in the Innovative Health segment was driven by a 5% rise in vaccines sales, a 5% rise in oncology sales, a 33% rise in inflammation and immunology sales, and a 1% rise in consumer healthcare sales.